Movement Alert|Ultragenyx Pharmaceutical Intraday Rise 5.03% in Regular Trading, London investor meeting and UK review progress support sentiment

Market Focus
Nov 19

On November 19, Ultragenyx Pharmaceutical rose 5.03% in Regular Trading, trading at $17.56 with turnover of $38.32 million.

The move aligned with recent company updates indicating it will participate in a London investor meeting, while the UK MHRA has accepted the marketing application for UX111 for Sanfilippo syndrome type A, helping improve near-term market sentiment.

Background context shows UX111 has entered the UK regulatory review process, a meaningful milestone for one of Ultragenyx Pharmaceutical’s rare-disease gene therapy candidates. Earlier analyst actions also reflected a constructive longer-term view: RBC Capital raised its price target to $40 from $35 while maintaining Outperform, and Wedbush lifted its target to $30 from $26 while keeping a Neutral rating.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10